Receptos is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics for immune diseases. Their lead program, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of their development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Phase II clinical trials are ongoing in RMS and IBD and data are expected in mid-2014. A Phase III trial in RMS patients is expected to launch in late 2013 or early 2014, per an interim analysis of the Phase II study, and will be conducted as part of a Special Protocol Assessment (SPA) agreement with the FDA.